XENE Xenon Pharmaceuticals Inc
Price (delayed)
$31.46
Market cap
$2.41B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.01
Enterprise value
$2.27B
Xenon is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The Company is advancing a novel product pipeline of
Highlights
XENE's debt is down by 17% year-on-year and by 8% since the previous quarter
The net income has declined by 28% year-on-year and by 10% since the previous quarter
The quick ratio has contracted by 25% YoY and by 20% from the previous quarter
Key stats
What are the main financial stats of XENE
Market
Valuations
Earnings
Shares outstanding
76.54M
Market cap
$2.41B
Enterprise value
$2.27B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.18
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$279.3M
Net income
-$234.33M
EBIT
-$238.42M
EBITDA
-$234.61M
Free cash flow
-$184.46M
Per share
Balance sheet
Liquidity
EPS
-$3.01
EPS diluted
-$3.01
Free cash flow per share
-$2.37
Book value per share
$9.9
Revenue per share
$0
TBVPS
$10.25
Total assets
$798.14M
Total liabilities
$43.24M
Debt
$9.02M
Equity
$754.9M
Working capital
$599.67M
Debt to equity
0.01
Current ratio
17.85
Quick ratio
17.66
Net debt/EBITDA
0.57
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27.3%
Return on equity
-28.5%
Return on invested capital
-32.5%
Return on capital employed
-31.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XENE stock price
How has the Xenon Pharmaceuticals stock price performed over time
Intraday
2.68%
1 week
-9.55%
1 month
-15.02%
1 year
-24.14%
YTD
-19.74%
QTD
-6.23%
Financial performance
How have Xenon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$279.3M
Net income
-$234.33M
Gross margin
N/A
Net margin
N/A
The operating income is down by 30% year-on-year and by 9% since the previous quarter
The net income has declined by 28% year-on-year and by 10% since the previous quarter
Growth
What is Xenon Pharmaceuticals's growth rate over time
Valuation
What is Xenon Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.18
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 10% YoY and by 7% QoQ
The company's equity fell by 19% YoY and by 5% QoQ
XENE's price to book (P/B) is 16% lower than its last 4 quarters average of 3.7
Efficiency
How efficient is Xenon Pharmaceuticals business performance
XENE's return on invested capital is down by 18% since the previous quarter and by 16% year-on-year
Xenon Pharmaceuticals's return on equity has decreased by 15% QoQ and by 13% YoY
Xenon Pharmaceuticals's return on assets has decreased by 15% QoQ and by 14% YoY
Dividends
What is XENE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XENE.
Financial health
How did Xenon Pharmaceuticals financials performed over time
The quick ratio has contracted by 25% YoY and by 20% from the previous quarter
XENE's current ratio is down by 25% year-on-year and by 20% since the previous quarter
XENE's debt is 99% smaller than its equity
The company's equity fell by 19% YoY and by 5% QoQ
XENE's debt is down by 17% year-on-year and by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.